Brotizolam

Brotizolam is a sedative-hypnotic thienodiazepine drug that is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines including triazolam. Brotizolam is indicated in 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 – 7.9 hours). Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan. It is grouped under the following drug class(es): Benzodiazepines, Hypnotics, Schedule IV controlled substances and Sedatives. Its therapeutic use is listed as sleeping drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lendormin, Mederantil, Sintonal and Nimbisan. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 2451.